What does Cartesian Therapeutics, Inc. do?
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA),…
What is Cartesian Therapeutics, Inc.'s P/E and P/B ratio?
Cartesian Therapeutics, Inc. has a P/E ratio of -1.1 and a P/B ratio of -1.49.
What is Cartesian Therapeutics, Inc.'s debt-to-equity ratio?
Cartesian Therapeutics, Inc. has a debt-to-equity ratio of -0.10.
How much does Cartesian Therapeutics, Inc. owe compared with what it owns?
Cartesian Therapeutics, Inc. owes $1.39 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Cartesian Therapeutics, Inc.'s Positivity rank?
Cartesian Therapeutics, Inc. is ranked #6,366 of 6,775 companies globally and #3,637 of 3,999 in United States on PositoAI, with a Positivity Score of -17,572.
Does Cartesian Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cartesian Therapeutics, Inc..
Where can I read the latest news about Cartesian Therapeutics, Inc.?
Recent headlines about Cartesian Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Cartesian Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Cartesian Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.